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ABSTRACT
The aim of this study was to develop and validate a new in-vitro kinetic model for the combination of
two drugs with different half-lives, and to use this model for the study of the pharmacodynamic effects
of amphotericin B and voriconazole, alone or in combination, against a strain of Candida albicans. Bolus
doses of voriconazole and amphotericin B were administered to a starting inoculum of C. albicans.
Antifungal-containing medium was eliminated and replaced by fresh medium using a peristaltic pump,
with the ﬂow-rate adjusted to obtain the desired half-life of the drug with the shorter half-life. A
computer-controlled dosing pump compensated for the agent with the longer half-life. Voriconazole and
amphotericin B half-lives were set to 6 and 24 h, respectively. Pharmacokinetic parameters were close to
target values when both single doses and sequential doses were simulated. Voriconazole and
amphotericin B administered alone demonstrated fungistatic and fungicidal activity, respectively.
Simultaneous administration resulted in fungicidal activity, whereas pre-exposure of C. albicans to
voriconazole, followed by amphotericin at 8 and 32 h, resulted in fungistatic activity similar to that
observed with voriconazole alone. Using this model, which allowed a combination of antifungal agents
with different half-lives, it was possible to demonstrate an antagonistic effect of voriconazole on the
fungicidal activity of amphotericin B. The characteristics and clinical relevance of this interaction require
further investigation.
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INTRODUCTION
Since the 1960s, the increase in the number of
patients with immunosuppression and ⁄ or other
risk-factors in modern healthcare has resulted in
an increase in invasive infections caused by
Candida spp. [1]. Invasive Candida infection is
now the fourth most common cause of nosocomial
bloodstream infection in the USA [2]. Despite
treatment, the mortality associated with severe
Candida infections is substantial [3]. During the
past decade, new antifungal agents have been
developed that give the clinician an opportunity to
choose from a broader arsenal of drugs for the
treatment of invasive fungal infections. Moreover,
there is now a greater possibility of combining
agents with different modes of action to achieve an
additive or synergic action for the most severely-ill
patients. Clinical studies are difﬁcult to perform
with this group of patients, and there are insufﬁ-
cient and somewhat conﬂicting data from in-vitro
studies, animal models and clinical reports on the
relative efﬁcacy of different antifungal combina-
tions. Clearly, before combining agents, it is
important to at least rule out antagonistic effects
that could be deleterious to patients.
Testing the in-vitro effect of combinations is
often performed with chequerboard titration or
time-kill studies in which the drug concentrations
are constant [4]. Very few in-vitro kinetic models
have been described for use in the ﬁeld of
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antifungal pharmacodynamics. However, Lewis
et al. [5] described an in-vitro kinetic model in
which they studied ﬂuconazole and amphotericin
B, either alone or in combination, against Candida
albicans. When administered alone, ﬂuconazole
and amphotericin B demonstrated fungistatic and
fungicidal activity, respectively, and when the
two drugs were administered simultaneously,
fungicidal activity similar to that observed with
amphotericin B alone was observed. However,
when ﬂuconazole was administered before amph-
otericin B, the fungicidal effect of amphotericin B
was lost, and only fungistatic activity, similar to
that obtained with ﬂuconazole alone, was
observed. Nevertheless, the usefulness of the
model described by Lewis et al. [5] was limited
by the fact that only one half-life was simulated.
In the case of the combination of voriconazole and
amphotericin B (half-lives of 6 h and 24 h,
respectively), this model cannot be used for the
simulation of human pharmacokinetics.
Blaser et al. [6] used an in-vitro model that
allowed the combination of two drugs with
different half-lives, the theoretical considerations
of which have been discussed previously [7].
Nevertheless, this model was rather complicated.
Therefore, the primary aim of the present study
was to develop and evaluate a simpliﬁed in-vitro
kinetic model for investigating a combination of
two drugs with different half-lives. A further goal
was to use this model for a pilot study of the
pharmacodynamic effects of amphotericin B and
voriconazole, alone or in combination, against a
strain of C. albicans.
MATERIALS AND METHODS
Fungal strain
A suspension of C. albicans CCUG 32723 (Culture Collection,
University of Go¨teborg, Sweden) was prepared from a 24–48-h
culture, from which one or two colonies were transferred into
test tubes containing 4 mL of RPMI-1640 medium and incu-
bated at 35C for 6 h, resulting in a standardised concentration
of c. 107 CFU ⁄mL.
MIC determination
MICs were determined using CLSI (formerly NCCLS) meth-
odology for broth dilution antifungal susceptibility testing of
yeasts [8]. The susceptibility endpoint for voriconazole was
deﬁned as the lowest concentration of the drug that resulted in
an 80% reduction in visible growth. The MIC of amphotericin
B was deﬁned as the lowest concentration that resulted in total
inhibition of visible growth.
Medium
Sterile RPMI-1640 buffered to pH 7.0 with 0.165 M morpho-
linepropanesulphonic acid was used as the growth medium.
Antifungal agents
Voriconazole (Pﬁzer AB, Ta¨by, Sweden) and amphotericin B
deoxycholate (Sigma-Aldrich, Stockholm, Sweden) were
obtained as sterile powders. Voriconazole and amphotericin
B were dissolved in 1 mL of dimethylsulphoxide (Sigma-
Aldrich) and diluted in RPMI-1640 to obtain the desired
concentrations. The antifungal solutions were prepared imme-
diately before each experiment.
In-vitro kinetic model
A one-compartment in-vitro kinetic model allowing exposure
of C. albicans to simulated human serum pharmacokinetics for
voriconazole and amphotericin B was constructed. This model
was a modiﬁed version of an in-vitro kinetic model described
previously by Lo¨wdin et al. [9] (Fig. 1). The culture vessel
(Bellco Glass, Vineland, NJ, USA), with a total volume of
115 mL, contained a magnetic stir bar for continuous mixing,
and had one side-arm with a silicone membrane for sampling
and addition of the drugs studied, and one side-arm connected
by a thin plastic tube to a vessel for waste. Fresh medium was
supplied to the culture vessel with a peristaltic pump (Model
403U ⁄VM4; Watson-Marlow Alitea, Stockholm, Sweden) con-
nected via a latex tube to the culture vessel. The ﬂow-rate was
adjusted to obtain the desired half-life of the antifungal agent.
In regimens in which two agents with different half-lives were
used, a computer-controlled dosing pump (Dosing-Pump
55-2222; Harvard Apparatus, Holliston, MA, USA) was used
to introduce the agent with the longer half-life through a
syringe connected via a plastic tube to the culture vessel.
E
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Fig. 1. Schematic illustration of the
in-vitro kinetic model. A, vessel
containing drug-free medium; B,
culture vessel; C, vessel for waste;
D, peristaltic pump adjusted for the
agent with the shorter half-life; E,
computer-controlled dosing pump
adjusted for the infusion of the
compensatory amount of the agent
with the longer half-life; F, port for
sampling and injection of drugs.
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ARUComb v.1.5 software (Snowfall Communications, Upp-
sala, Sweden) was used to program the pump to introduce the
drug at an exponentially decreasing rate. The in-vitro model
was placed in a thermostatically controlled room at 35C
during the experiments. The equipment was sterilised by
autoclaving between each experiment.
Pharmacokinetic analysis
The antifungal agents were eliminated at a constant rate
according to the ﬁrst-order kinetics of C = C0 · e–kt, where C0
is the initial concentration, C is the concentration at time t, k is
the rate of elimination, and t is the time that has elapsed since
administration of the drug. The constant k is similar to F ⁄V,
where F is the dilution ﬂow-rate and V is the volume of the
compartment. Using this equation, the ﬂow-rate needed to
obtain a particular half-life could be calculated.
To verify the pharmacokinetics of the model, vancomycin
was used to simulate the pharmacokinetics of voriconazole
and amphotericin B in experiments at room temperature
without yeasts. Two regimens were simulated: vancomycin
100 mg ⁄L at 0 h (simulating the 6-h half-life of voriconazole
[10]) and vancomycin 25 mg ⁄L at 0 h (simulating the 24-h half-
life of amphotericin B [11]). Each experimental regimen was
tested in triplicate. The dose in the experiment with the longer
half-life was repeated after 24 and 48 h to study the effect of
accumulation in the model. The ﬂow-rate of the peristaltic
pump was 12.7 mL ⁄h in both the 6-h half-life and the 24-h
half-life experiments. In the latter regimen, syringes containing
vancomycin 2500 mg ⁄L, compensating for the longer half-life,
were placed in the dosing pump. In the regimen with
vancomycin simulating the 24-h half-life of amphotericin B,
the total volume of the waste divided by the time of the
experiment was used to conﬁrm the 12.7 mL ⁄h ﬂow-rate, and
thus the 6-h half-life (data not shown).
Vancomycin (Abbot Scandinavia, Solna, Sweden) was
obtained as a sterile powder and dissolved in sterile phos-
phate-buffered saline, pH 7.2. The antibiotic solution was
prepared immediately before each experiment, and 110 mL of
phosphate-buffered saline was used as the medium. Vanco-
mycin (1 mL) solution was added through one side-arm of the
culture vessel to yield the desired starting concentration.
Repeated sampling of c. 0.25 mL was performed over 24 and
72 h for regimens simulating voriconazole and amphotericin
B, respectively. Samples were stored frozen at )70C until
analysis. Drug concentrations were measured on an Abbot
Architect ci8200 analyser (Abbot Diagnostics, Solna, Sweden).
Emit 2000 Vancomycin Reagent (Dade Behring, Stockholm,
Sweden) was used for the vancomycin assay. Accuracy was
high (r2 = 0.97) and there was a low coefﬁcient of variation
(3.7%) in the range 1–35 mg ⁄L.
Killing experiments with a simulated kinetic proﬁle
Different antifungal regimens were simulated in the model.
These included: (i) the control (no drug); (ii) voriconazole at
0 h; (iii) amphotericin B at 0 h; (iv) voriconazole and ampho-
tericin B at 0 h; and (v) voriconazole at 0 h and amphotericin B
at 8 and 32 h. Each experimental regimen was tested in
triplicate. C. albicans suspension (0.1 mL) was added to 110 mL
of RPMI-1640 through one side-arm to yield a starting inoculum
of c. 104 CFU ⁄mL. Voriconazole and ⁄or amphotericin B
solutions (0.25–0.5 mL) were added through one side-arm to
yield starting concentrations of 5 mg ⁄L and 2.5 mg ⁄L, respect-
ively. The voriconazole doses in experiments (ii), (iv) and
(v) were the same, as were each of the amphotericin B doses in
experiments (iii), (iv) and (v). Serum protein binding for
voriconazole and amphotericin B is 60% and 90%, respectively
[11,12]; the experiments simulated the free concentration of
voriconazole. The initial voriconazole concentration was
chosen to represent a high drug level in the range of peak
concentrations observed in plasma after clinically relevant
doses [13]. In order to achieve a maximal fungicidal effect, the
amphotericin B level was somewhat higher than those found in
clinical practice; however, the concentration chosen was similar
to that used previously in in-vitro experiments [5]. The ﬂow-
rate of the peristaltic pump was adjusted to obtain the desired
half-life of 6 h for voriconazole [10]. To achieve a half-life of
24 h for amphotericin B [11], the computer-controlled dosing
pump was prepared with an amphotericin B solution contain-
ing 200 mg ⁄L. Repeated sampling at different time-points for
viable counting was performed through the silicone mem-
brane. The samples were serially diluted ten-fold in phosphate-
buffered saline. At least three samples (10 or 100 lL) from the
original fungal suspension and ⁄or dilutions were spread
subsequently on Sabaraud-dextrose agar plates, incubated at
35C and counted after 48 h. The limit of detection of the viable
counts was 1 · 101 CFU ⁄mL. Fungicidal and fungistatic effects
were deﬁned as a reduction, in CFU ⁄mL, from the starting
inoculum of ‡99.9% and <99.9%, respectively [14].
Antifungal agent carryover
To avoid carryover of antifungal agents, all samples were
plated as a single spot on Sabaraud-dextrose agar plates and
allowed to diffuse into the agar for 3–5 min before spreading. If
antifungal carryover was present, a clear zone was visible after
incubation at the position where the sample had been placed;
in such cases, the agar plate was divided into sections and the
clear section was excluded from counting. To study the effect
of carryover with this method, undiluted and 100-fold diluted
samples containing 2.5 and 5 mg ⁄L of amphotericin B and
voriconazole were spread on Sabaraud-dextrose agar plates.
This resulted in negligible carryover, with mean log10 CFU ⁄mL
counts that were 1.5% and 1% higher in the diluted samples
for amphotericin B and voriconazole, respectively.
Statistics
Values are reported as means ± SD unless otherwise stated.
RESULTS
MIC determination
The MICs of voriconazole and amphotericin B for
C. albicans CCUG 32723 were 0.004 and
0.25 mg ⁄L, respectively.
Pharmacokinetic analysis
The results of the pharmacokinetic analysis of
the kinetic model with vancomycin simulating
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voriconazole, and repeated doses of amphotericin
B with half-lives of 6 and 24 h, respectively, are
shown in Fig. 2. The values (means ± SE) were
close to those expected and the half-lives obtained
with one dose were 6.4 ± 0.6 and 23.7 ± 1.2 h,
respectively. The simulated amphotericin B con-
centrations before the second and the third dose
in the 24-h half-life experiment were 12.3 ± 0.3
and 19.7 ± 0.3 mg ⁄L, respectively, which did not
affect the half-lives after repeated doses, the mean
of which was 24.9 ± 2.6 h.
Killing experiments with a simulated kinetic
proﬁle
Time-kill curves for the different regimens are
shown in Fig. 3. For the unexposed control, there
was a c. 3 log10 increase in CFU ⁄mL, demonstrat-
ing the viability of the C. albicans strain and the
lack of growth-inhibiting substances in the med-
ium. Administration of voriconazole resulted in
fungistatic activity, whereas the administration
of amphotericin B resulted in a fungicidal
effect. When voriconazole was combined with
amphotericin B and administered simultaneously,
the number of C. albicans CFUs was below the
detection limit after 3 h, which did not differ from
the rapid fungicidal effect of amphotericin B
alone. In contrast, when amphotericin B was
administered after voriconazole exposure for
8 h, the fungicidal activity was abolished
(3.9 ± 0.1 log10 CFU ⁄mL before the amphotericin
B dose and 3.9 ± 0.4 log10 CFU ⁄mL after 4 h).
Similarly, there was no fungicidal effect following
a second dose of amphotericin B administered at
32 h (5.2 ± 0.1 log10 CFU ⁄mL before the second
amphotericin B dose and 5.0 ± 0.3 log10 CFU ⁄mL
after a further 4 h).
DISCUSSION
Because of the poor prognosis of fungal infec-
tions, there is increasing interest in combination
therapy. Clinical studies evaluating the effect of
different antifungal treatments, alone or in com-
bination, in patients with invasive fungal diseases
are very difﬁcult to perform, with many non-
drug-related factors that may affect the outcome
[15]. Experimental pharmacodynamic studies
yielding data concerning drug-speciﬁc antifungal
activity are therefore of particular interest.
Very few in-vitro kinetic models have been
described for combination therapy with antifungal
agents [5]. Human serum pharmacokinetics can
be simulated in kinetic models, which is an
advantage compared with most other in-vitro
techniques in which fungi are exposed to constant
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Fig. 2. Target and experimental pharmacokinetics of
(a) voriconazole and (b) amphotericin B simulated with
vancomycin regimens. The values plotted are means ± SE
of three experiments. VORI, vancomycin regimen simula-
ting one dose of voriconazole; AMB, vancomycin regimen
simulating three repeated doses of amphotericin B.
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Fig. 3. Time-kill plots of voriconazole and amphotericin B
regimens against Candida albicans CCUG 32723 in the in-
vitro kinetic model. The values plotted are means ± SD of
three experiments. Control, no drug; VORI, voriconazole
administered at 0 h; AMB, amphotericin B administered at
0 h; Simult, simultaneous administration of voriconazole
and amphotericin B at 0 h; Pre-exposure, voriconazole
administered at 0 h and amphotericin B at 8 and 32 h.
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drug concentrations, and with animal models in
which there are difﬁculties in simulating human
pharmacokinetics. The in-vitro antifungal kinetic
model described by Lewis et al. [5] allows com-
binations of drugs with the same half-life to be
tested. However, when establishing a model in
which combinations of two antibacterial or anti-
fungal drugs with different half-lives can be
studied, several additional considerations need
to be addressed. The present model, in compar-
ison to the rather complicated method described
by Blaser and colleagues [6,7], has the advantage
of fewer vessels and connections, and is thus
easier to handle, with less risk of leakage and
contamination. In the present model, the addition
of low volumes at high concentration using a
computer-controlled dosing pump was used to
simulate the kinetics of the drug with the longer
half-life. This caused a negligible increase in the
total ﬂow-rate (<1%).
In order to validate the half-life precision of this
model, vancomycin was used to study the kinet-
ics. This choice was made since, at this hospital,
there is a well-established method for concentra-
tion analysis with very high accuracy and preci-
sion. The doses of vancomycin in the different
regimens were chosen in order to maintain the
concentration between doses with the highest
precision. Concentration analysis of voriconazole
and amphotericin B with higher coefﬁcients of
variation [16,17] would have led to a lower
precision in the determination of the half-lives
under investigation. As shown in Fig. 2, the
concentration–time curves of vancomycin fol-
lowed the expected patterns closely. For the
regimen in which vancomycin simulated the
24-h half-life of amphotericin B, the total volume
of waste divided by the time of the experiment
was used to conﬁrm the 12.7 mL ⁄h ﬂow-rate, and
thus the simulated 6-h half-life of voriconazole.
Overall, this in-vitro kinetic model was shown to
have good precision, and can thus be used to
study combinations of drugs with different half-
lives. Furthermore, the model can be extended
easily by using additional pumps with pro-
grammed infusion rates to simulate more com-
plex situations, e.g., combinations of more than
two drugs with different half-lives, or the phar-
macokinetics after oral absorption.
Several studies have explored the potential
antagonism between amphotericin B and azole
agents in the treatment of infections caused by
Candida spp. There is a theoretical concern that
azole agents will inﬂuence the activity of amph-
otericin B negatively, since there will be less
ergosterol available for the polyene to bind to as a
result of the azole inhibiting ergosterol synthesis
[18,19]. Sud and Feingold [20] observed the
development of amphotericin resistance after
pre-treatment of C. albicans with ketoconazole,
and showed that ergosterol depletion paralleled
the observed development of amphotericin B
resistance. In-vitro studies, animal models and
clinical reports concerning this phenomenon have
been reviewed previously, with mixed conclu-
sions [21,22]. Most in-vitro studies have reported
antagonism, but in some studies that failed to
observe antagonism between an azole and amph-
otericin B, the drugs were administered simulta-
neously. In such cases, there is probably no time
for the azole to affect the receptor before the
fungal cell is killed by the action of amphotericin
B. Lewis et al. [5] reported antagonism when
ﬂuconazole was administered before amphoteri-
cin B, but amphotericin B alone showed a rapid
fungicidal effect on C. albicans, which could not be
detected if amphotericin B was given 8 h or 32 h
after a previous dose of ﬂuconazole. This effect
has also been observed in a rabbit model in which
amphotericin B administered after treatment with
ﬂuconazole resulted in slower clearance of fungi
from infected tissues than after treatment with
amphotericin B alone [23].
The present study investigated whether there is
a similar antagonistic effect between the new
azole, voriconazole, and amphotericin B, using
the same time-points for amphotericin B admin-
istration that were used in the study by Lewis
et al. [5]. The present in-vitro kinetic model
showed that the 24-h half-life of amphotericin B
could be established concomitantly with a 6-h
half-life of voriconazole. The amphotericin B
dosing schedule was equivalent to the clinical
approach, with 24-h dosing intervals. Commence-
ment of amphotericin B treatment 8 h after the
last voriconazole dose might occur in situations in
which the response to voriconazole has been
considered insufﬁcient or found to be contraindi-
cated. The results indicate that no inhibition
occurs when amphotericin B and voriconazole
are given simultaneously, whereas the fungicidal
effect is abolished when amphotericin B is given
8 h and 32 h after the dose of voriconazole. Thus,
the ﬁndings of Lewis et al. [5] concerning the
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combination of ﬂuconazole and amphotericin B
were also conﬁrmed for voriconazole. The pre-
served fungicidal effect of amphotericin B in the
presence of high voriconazole concentrations
given simultaneously indicates that the effect
cannot be explained by physico-chemical binding
and inactivation of amphotericin B.
The clinical relevance of this antagonism
between azoles and amphotericin B has not yet
been established. In a clinical trial by Rex et al.
[24], often referred to in this context, ﬂuconazole
alone was compared with a combination of
ﬂuconazole and amphotericin B, with a trend to
improved efﬁcacy in patients treated with the
combination. This observation is consistent with
experimental in-vitro and animal data demon-
strating a fungicidal effect of amphotericin B in
combination with ﬂuconazole if both drugs are
given concomitantly from the start, which differs
from the fungistatic effect achieved by ﬂuconaz-
ole alone. In the study by Rex et al. [24], no
comparison was made between the combination
treatment and amphotericin B alone.
Voriconazole has been considered to be one of
the options for empirical antifungal therapy in
patients with neutropenia and persistent fever
[25]. A fungicidal effect of the treatment in these
patients may be of importance, particularly if there
is a need to change the antifungal regimen from
voriconazole to an amphotericin B preparation. In
such cases, the interaction demonstrated in this
study might be of clinical relevance.
In summary, the present study described and
validated a new, simpliﬁed in-vitro kinetic
model for the study of combination treatment
involving drugs with different half-lives. The
model demonstrated an antagonistic effect of
voriconazole on the fungicidal activity of sequen-
tial doses of amphotericin B against one strain of
C. albicans. The inﬂuence of varying the drug
concentrations and the duration of treatment, as
well as the strain speciﬁcity and the clinical
relevance of this phenomenon, all require further
investigation.
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